KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $428.3 million.

  • Vertex Pharmaceuticals' Other Accumulated Expenses rose 1798.9% to $428.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $428.3 million, marking a year-over-year increase of 1798.9%. This contributed to the annual value of $428.3 million for FY2025, which is 1798.9% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $428.3 million for Q4 2025, which was up 1798.9% from $441.5 million recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Other Accumulated Expenses peaked at $648.6 million during Q1 2024, and registered a low of $201.4 million during Q3 2021.
  • Over the past 5 years, Vertex Pharmaceuticals' median Other Accumulated Expenses value was $336.9 million (recorded in 2023), while the average stood at $348.8 million.
  • In the last 5 years, Vertex Pharmaceuticals' Other Accumulated Expenses skyrocketed by 7204.24% in 2024 and then plummeted by 4042.55% in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $268.4 million in 2021, then rose by 16.06% to $311.5 million in 2022, then surged by 69.25% to $527.2 million in 2023, then tumbled by 31.15% to $363.0 million in 2024, then grew by 17.99% to $428.3 million in 2025.
  • Its Other Accumulated Expenses was $428.3 million in Q4 2025, compared to $441.5 million in Q3 2025 and $425.4 million in Q2 2025.